It will be interesting to see what drug sales are like during this pandemic. certainly the elective stuff like botox will take a very large hit. However other meds that are not in the elective category are not immune. I can see some of the anti-inflammatory drugs dip on concerns about immunosuppression. Even meds for serious conditions could see some shifts. e.g. less ocrevus and more copaxone (and even avonex) due to perceived safety wrt infections and the ability to self administer at home vs having to make a trip to a doctors office. Social distancing might mean rethinking options for cancer regimens - e.g. will Darzalex be pushed back to later line now in light of the fact it is a slow infusion in a doctors office (until the SC formulation comes to market).
bottom line I think it is not just the elective stuff that will be affected (and disruptions could persist even as restrictions are eased as docs have to rethink how they deliver care - more telemedicine to lessen crowds in waiting rooms, waiting rooms should create conducive atmosphere to continue social distancing for a while. This will cause work flow disruptions that can eat into volumes that come through the office.
It's time to at least consider possible winners and losers in the age of covid - vaccine makers are looking good, essential drugs looking good, drugs that minimize doctor visits, and so on
JMO
Market Data 
Markets 
AI
